Asset
Ontunisertib
AgomAb Therapeutics NV American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07118878 | phase1 | completed | 2025-08-06 | 2025-09-15 | Agomab Spain S.L.U. | A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants |
| NCT05937386 | phase1 | completed | 2023-08-09 | 2023-09-06 | Agomab Spain S.L. | Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants |
| NCT06397508 | phase1 | completed | 2024-04-02 | 2024-05-08 | Agomab Spain S.L. | Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants |
| NCT05843578 | phase2 | completed | 2023-08-01 | 2026-06-20 | Agomab Spain S.L.U. | STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease |
FDA applications (0)
This company has no applications containing this asset.